Longeveron Inc. (LGVN)

Market Cap	7.91M -53.6%
Revenue (ttm)	1.19M -42.7%
Net Income	-23.47M
EPS	-9.73
Shares Out	3.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	58,440
Open	2.400
Previous Close	2.370
Day's Range	2.340 - 2.600
52-Week Range	2.300 - 12.300
Beta	-0.20
Analysts	Buy
Price Target	61.25 (+2,369.76%)
Est. Earnings	Nov 3, 2026

About LGVN

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer’s disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 12, 2021
• Employees: 38
• Stock Exchange: Nasdaq
• Ticker Symbol: LGVN
• Website: https://longeveron.com

Financial Performance

In 2025, Longeveron's revenue was $1.20 million, a decrease of -49.87% compared to the previous year's $2.39 million. Losses were -$22.70 million, -7.79% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for LGVN stock is "Buy." The 12-month stock price target is $61.25, which is an increase of 2,369.76% from the latest price.

Price Target

$61.25

(2,369.76% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error